List view / Grid view
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
The outlook for brain tumour patients is pretty negative, with the median survival rate for patients with glioblastoma multiforme, or GBM, a mere 14.2 months.
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Cell Medica has expanded its partnership with Baylor College of Medicine to develop an off-the-shelf allogeneic cell therapy, using T (NKT) cells...
21 June 2016 | By Victoria White, Digital Content Producer
A Penn Medicine preclinical study shows how an antibody - carbohydrate combination CAR T cell therapy could apply to range of cancer types...
16 June 2016 | By Victoria White, Digital Content Producer
Salk Institute researchers have imaged how vital receptors on the surface of T cells bundle together when activated using super-resolution microscopy...
2 June 2016 | By Victoria White, Digital Content Producer
The new collaboration builds on an earlier agreement with LUMC that gave Bellicum worldwide rights to TCR product candidates targeting solid tumours...
25 April 2016 | By Victoria White, Digital Content Producer
Researchers at the University of Dundee have made new discoveries about the importance of nutrients for a subpopulation of T-cells...
21 April 2016 | By Victoria White, Digital Content Producer
ARGX-115 targets the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells...
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
22 March 2016 | By Victoria White
Celyad is teaming up with the Inserm Unit of Institut Curie in Paris, France, to further develop its NKR-T pipeline in cellular immunotherapies for cancer...
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
